World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
29460
World Ranking
16954
National Ranking
8502

Overview

Frits van Rhee is affiliated with the University of Arkansas for Medical Sciences in the United States. Their research primarily spans the field of medicine, with particular focus in hematology, oncology, molecular biology, pathology and forensic medicine, and genetics.

The scientist's work covers multiple specialized topics that include:

  • Multiple Myeloma Research and Treatments
  • Viral-associated cancers and disorders
  • Protein Degradation and Inhibitors
  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Peptidase Inhibition and Analysis
  • Cancer Treatment and Pharmacology

Their recent notable publications include:

  • "International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease," 2020, Blood Advances
  • "The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma," 2021, Nature Communications
  • "Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis," 2023, Blood Advances
  • "Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease," 2021, American Journal of Hematology
  • "Long-term outcomes after autologous stem cell transplantation for multiple myeloma," 2020, Blood Advances

Frits van Rhee collaborates frequently with several researchers including Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Samer Al Hadidi, and John D. Shaughnessy. These collaborations have resulted in substantial joint publications.

The scientist often publishes in venues such as:

  • Blood
  • Cytotherapy
  • Blood Advances
  • American Journal of Hematology
  • Journal of Clinical Oncology

Best Publications

  • The molecular classification of multiple myeloma

    Fenghuang Zhan;Yongsheng Huang;Yongsheng Huang;Simona Colla;Simona Colla;James P. Stewart;James P. Stewart

  • A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

    John D. Shaughnessy;Fenghuang Zhan;Bart E. Burington;Yongsheng Huang

  • Thalidomide and hematopoietic-cell transplantation for multiple myeloma

    Bart Barlogie;Guido Tricot;Elias Anaissie;John Shaughnessy

  • Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

    Fenghuang Zhan;Johanna S. Hardin;Bob Kordsmeier;Klaus Bumm

  • CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

    Eric D. Hsi;Roxanne Steinle;Balaji Balasa;Susann Szmania

  • International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

    David C. Fajgenbaum;Thomas S. Uldrick;Adam Bagg;Dale Frank

  • Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

    Ichiro Hanamura;James P. Stewart;James P. Stewart;Yongsheng Huang;Yongsheng Huang;Fenghuang Zhan;Fenghuang Zhan

  • F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

    Twyla B. Bartel;Jeff Haessler;Tracy L. Y. Brown;John D. Shaughnessy

  • Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications

    Ronald Walker;Bart Barlogie;Jeffrey Haessler;Guido Tricot

  • Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

    Fenghuang Zhan;Bart Barlogie;Varant Arzoumanian;Yongsheng Huang

  • Siltuximab for multicentric Castleman's disease: A randomised, double-blind, placebo-controlled trial

    Frits van Rhee;Raymond S M Wong;Nikhil C Munshi;Jean-François Rossi

  • Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse

    F. Van Rhee;Feng Lin;J. O. Cullis;A. Spencer

  • A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

    Jeffrey A. Zonder;Ann F. Mohrbacher;Seema Singhal;Frits van Rhee

  • Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

    Saad Z. Usmani;Christoph Heuck;Alan Mitchell;Jackie Szymonifka

  • International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

    Frits Van Rhee;Peter Voorhees;Angela Dispenzieri;Alexander Fosså

  • Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

    Bart Barlogie;Elias Anaissie;Frits Van Rhee;Jeffrey Haessler

  • HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

    David C. Fajgenbaum;Frits van Rhee;Christopher S. Nabel

  • Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo

    Elaine M. Sloand;Sonnie Kim;Jaroslaw P. Maciejewski;Fritz Van Rhee

  • Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.

    Maurizio Zangari;Bart Barlogie;Elias Anaissie;Fariba Saghafifar

  • Idiopathic multicentric Castleman's disease: a systematic literature review

    Amy Y Liu;Christopher S Nabel;Brian S Finkelman;Jason R Ruth

Frequent Co-Authors

Bart Barlogie
Bart Barlogie Mount Sinai Hospital
Maurizio Zangari
Maurizio Zangari University of Arkansas for Medical Sciences
Joshua Epstein
Joshua Epstein University of Arkansas for Medical Sciences
Gareth J. Morgan
Gareth J. Morgan Boston University
Faith E. Davies
Faith E. Davies New York University Langone Medical Center
Elias Anaissie
Elias Anaissie University of Cincinnati
John D. Shaughnessy
John D. Shaughnessy University of Arkansas for Medical Sciences
Guido Tricot
Guido Tricot University of Iowa
Brian A Walker
Brian A Walker Indiana University – Purdue University Indianapolis
Saad Z. Usmani
Saad Z. Usmani Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine or healthcare but want to explore alternative or complementary pathways, online degrees offer greater flexibility and accessibility. For those interested in healthcare management, understanding how to evaluate healthcare administration degree programs is crucial. Look for accreditation, faculty experience, and student support when choosing the right fit.

Nurses hoping to advance their careers may turn to fully online RN to BSN programs designed for working professionals. Some options, such as rn to bsn online no clinicals, eliminate the need for in-person clinical hours, making them even more accessible.

For those aiming for leadership roles in nursing, Doctor of Nursing Practice programs are now widely available. Explore dnp programs online to find the fastest options, or seek out the dnp programs online that emphasize flexibility and student support.

These online pathways can open doors to advanced positions in healthcare, support work-life balance, and help you take the next step on your professional journey.

Best Scientists Citing Frits van Rhee

Trending Scientists